HDAC3 and small cell lung carcinoma: We found that HDAC3 may regulate the accessibility of the promoter and inhibit the transcription of NKG2DL by deacetylating histone H3K9ac and the treatment with HDAC3 specific inhibitors increased the acetylation level of H3K9 (Figure 4F) and up-regulated NKG2DL expression in SCLC-N cells (Figure 4C).